WO1999034833A1 - Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom - Google Patents
Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom Download PDFInfo
- Publication number
- WO1999034833A1 WO1999034833A1 PCT/US1999/000594 US9900594W WO9934833A1 WO 1999034833 A1 WO1999034833 A1 WO 1999034833A1 US 9900594 W US9900594 W US 9900594W WO 9934833 A1 WO9934833 A1 WO 9934833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- peg
- group
- alkyl
- formula
- Prior art date
Links
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 87
- -1 poly(ethylene glycol) Polymers 0.000 title claims abstract description 29
- 239000000499 gel Substances 0.000 title description 16
- 150000001252 acrylic acid derivatives Chemical class 0.000 title description 8
- 239000000017 hydrogel Substances 0.000 claims abstract description 53
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 16
- 230000008878 coupling Effects 0.000 claims abstract description 4
- 238000010168 coupling process Methods 0.000 claims abstract description 4
- 238000005859 coupling reaction Methods 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 15
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 125000000524 functional group Chemical group 0.000 claims description 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 7
- 150000002466 imines Chemical class 0.000 claims description 6
- 150000002019 disulfides Chemical class 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 150000002905 orthoesters Chemical class 0.000 claims description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 238000007334 copolymerization reaction Methods 0.000 claims description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 2
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 claims 2
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 12
- 238000006116 polymerization reaction Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000003301 hydrolyzing effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 229920002554 vinyl polymer Polymers 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 229920000058 polyacrylate Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000001241 acetals Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 108010006205 fluorescein isothiocyanate bovine serum albumin Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000013077 target material Substances 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000012966 redox initiator Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002316834A CA2316834C (en) | 1998-01-07 | 1999-01-06 | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
EP99902172A EP1053019B1 (en) | 1998-01-07 | 1999-01-06 | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
DK99902172T DK1053019T3 (en) | 1998-01-07 | 1999-01-06 | Degradable heterobifunctional polyethylene glycol acrylates and gels and conjugates derived therefrom |
JP2000527280A JP3786832B2 (en) | 1998-01-07 | 1999-01-06 | Degradable heterobifunctional poly (ethylene glycol) acrylate and gels and composites derived therefrom |
AT99902172T ATE255422T1 (en) | 1998-01-07 | 1999-01-06 | DEGRADABLE, HETEROBIFUNCTIONAL POLYETHYLENE GLYCOL ACRYLATES, AND GEL AND CONJUGATES THAT CAN BE PRODUCED THEM |
DE1999613316 DE69913316T2 (en) | 1998-01-07 | 1999-01-06 | DEGRADABLE, HETEROBIFUNCTIONAL POLYETHYLENE GLYCOL ACRYLATES, AND GELS AND CONJUGATES THAT CAN BE PRODUCED WITH THEM |
AU22214/99A AU755051B2 (en) | 1998-01-07 | 1999-01-06 | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7068098P | 1998-01-07 | 1998-01-07 | |
US60/070,680 | 1998-01-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999034833A1 true WO1999034833A1 (en) | 1999-07-15 |
WO1999034833A9 WO1999034833A9 (en) | 2005-03-17 |
Family
ID=22096751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000594 WO1999034833A1 (en) | 1998-01-07 | 1999-01-06 | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
Country Status (11)
Country | Link |
---|---|
US (7) | US6362276B1 (en) |
EP (1) | EP1053019B1 (en) |
JP (1) | JP3786832B2 (en) |
AT (1) | ATE255422T1 (en) |
AU (1) | AU755051B2 (en) |
CA (1) | CA2316834C (en) |
DE (1) | DE69913316T2 (en) |
DK (1) | DK1053019T3 (en) |
ES (1) | ES2211033T3 (en) |
PT (1) | PT1053019E (en) |
WO (1) | WO1999034833A1 (en) |
Cited By (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000014131A1 (en) * | 1998-09-07 | 2000-03-16 | Polybiomed Limited | Polymerizable material and sheet material derived therefrom |
WO2000015117A1 (en) | 1998-09-17 | 2000-03-23 | Focal, Inc. | Self-cleaning fluid delivery device for medical applications |
WO2001026692A1 (en) * | 1999-10-08 | 2001-04-19 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
WO2003005026A2 (en) * | 2001-07-02 | 2003-01-16 | Amersham Biosciences Uk Limited | Chemical capture reagent |
JP2003518178A (en) * | 1999-12-22 | 2003-06-03 | シアウォーター・コーポレイション | Sterically hindered derivatives of water-soluble polymers |
WO2004026145A2 (en) | 2002-09-20 | 2004-04-01 | Genzyme Corporation | Multi-pressure biocompatible agent delivery device and method |
WO2005061018A1 (en) * | 2003-12-22 | 2005-07-07 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring protein backbone |
WO2006003014A2 (en) * | 2004-07-05 | 2006-01-12 | Complex Biosystems Gmbh | Hydrogel polymeric conjugates of a prodrug |
EP1625856A1 (en) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
US7057019B2 (en) | 1996-09-23 | 2006-06-06 | Incept Llc | Crosslinked albumin hydrogels |
US7132475B2 (en) | 2000-10-19 | 2006-11-07 | Ecole Polytechnique Federale De Lausanne | Block copolymers for multifunctional self-assembled systems |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
US7338933B2 (en) | 2004-01-08 | 2008-03-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
WO2008060780A2 (en) | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
JP2008174755A (en) * | 2008-02-14 | 2008-07-31 | Nektar Therapeutics Al Corp | Hetero-bifunctional polyethylene glycol derivative and method for preparing it |
WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
US7413739B2 (en) | 1999-02-01 | 2008-08-19 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
EP2042196A2 (en) | 2001-10-10 | 2009-04-01 | Neose Technologies, Inc. | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7597882B2 (en) | 2006-04-24 | 2009-10-06 | Incept Llc | Protein crosslinkers, crosslinking methods and applications thereof |
EP2111872A3 (en) * | 2004-07-05 | 2009-12-23 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US7744912B1 (en) | 1999-02-01 | 2010-06-29 | Eidgenossische Technische Hochschule Zurich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US7842667B2 (en) | 2003-12-22 | 2010-11-30 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
WO2010144629A1 (en) | 2009-06-09 | 2010-12-16 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
EP2298354A2 (en) | 2001-10-10 | 2011-03-23 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-beta |
US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
EP2386571A2 (en) | 2005-04-08 | 2011-11-16 | BioGeneriX AG | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8076292B2 (en) | 2001-10-10 | 2011-12-13 | Novo Nordisk A/S | Factor VIII: remodeling and glycoconjugation of factor VIII |
WO2012065181A2 (en) | 2010-11-12 | 2012-05-18 | Dana Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
JP2012158759A (en) * | 2012-03-27 | 2012-08-23 | Nektar Therapeutics Al Corp | Heterobifunctional polyethylene glycol derivative, and method for preparing the same |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
EP2514757A2 (en) | 2005-01-10 | 2012-10-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US8372422B2 (en) | 2000-11-14 | 2013-02-12 | Nektar Therapeutics | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
US8404809B2 (en) | 2005-05-25 | 2013-03-26 | Novo Nordisk A/S | Glycopegylated factor IX |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
EP2586456A1 (en) | 2004-10-29 | 2013-05-01 | BioGeneriX AG | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
EP2518113A4 (en) * | 2009-12-24 | 2013-06-19 | Nisshinbo Holdings Inc | Resin crosslinking agent |
WO2013102211A2 (en) | 2011-12-29 | 2013-07-04 | Walensky Loren D | Stabilized antiviral fusion helices |
US8632770B2 (en) | 2003-12-03 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated factor IX |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8716239B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF |
US8716240B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
WO2014144148A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
WO2014151369A2 (en) | 2013-03-15 | 2014-09-25 | Dana-Farber Cancer Institute, Inc. | Stabilized ezh2 peptides |
US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
US9133276B2 (en) | 2010-09-17 | 2015-09-15 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an exendin linker conjugate |
US9138462B2 (en) | 2009-07-31 | 2015-09-22 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an insulin linker conjugate |
US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
US9175047B2 (en) | 2009-01-14 | 2015-11-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US9206223B2 (en) | 2008-09-22 | 2015-12-08 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
US9265723B2 (en) | 2009-07-31 | 2016-02-23 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
US9273099B2 (en) | 2003-11-05 | 2016-03-01 | President And Fellows Of Harvard College | Stabilized alpha helical peptides and uses thereof |
JP2016029182A (en) * | 2015-10-28 | 2016-03-03 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Hetero bifunctional polyethylene glycol derivative and preparation method thereof |
US9463004B2 (en) | 2009-05-04 | 2016-10-11 | Incept, Llc. | Biomaterials for track and puncture closure |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
US9505867B2 (en) | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US9505801B2 (en) | 1999-05-18 | 2016-11-29 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US9522947B2 (en) | 2011-10-18 | 2016-12-20 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US9617309B2 (en) | 2012-09-26 | 2017-04-11 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
US9687216B2 (en) | 2004-11-05 | 2017-06-27 | Incept, Llc | Methods for sealing a vascular puncture |
US9707252B2 (en) | 2005-02-09 | 2017-07-18 | Covidien Lp | Synthetic sealants |
JP2017197770A (en) * | 2017-06-27 | 2017-11-02 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Heterobifunctional polyethylene glycol derivative, and preparing method thereof |
US9845287B2 (en) | 2012-11-01 | 2017-12-19 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
WO2018039545A2 (en) | 2016-08-26 | 2018-03-01 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
US9957299B2 (en) | 2010-08-13 | 2018-05-01 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
US10081654B2 (en) | 2013-03-13 | 2018-09-25 | President And Fellows Of Harvard College | Stapled and stitched polypeptides and uses thereof |
WO2019018499A2 (en) | 2017-07-19 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
US10213477B2 (en) | 2012-02-15 | 2019-02-26 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US10227390B2 (en) | 2013-06-14 | 2019-03-12 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
US10227380B2 (en) | 2012-02-15 | 2019-03-12 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10301351B2 (en) | 2007-03-28 | 2019-05-28 | President And Fellows Of Harvard College | Stitched polypeptides |
US10300109B2 (en) | 2009-09-22 | 2019-05-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
WO2019157131A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
WO2019178313A1 (en) | 2018-03-14 | 2019-09-19 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for biomarker detection |
US10464975B2 (en) | 2015-07-02 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
US10471120B2 (en) | 2014-09-24 | 2019-11-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CN110668933A (en) * | 2019-09-30 | 2020-01-10 | 兰州交通大学 | Novel method for synthesizing allyl fatty alcohol polyoxyethylene ether carboxylic acid (APEA-7) |
US10533039B2 (en) | 2014-05-21 | 2020-01-14 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
CN110759824A (en) * | 2019-09-30 | 2020-02-07 | 兰州交通大学 | Novel method for synthesizing allyl fatty alcohol polyoxyethylene ether carboxylic acid (APEA-3) |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
WO2020215005A1 (en) | 2019-04-18 | 2020-10-22 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
WO2021127493A1 (en) | 2019-12-20 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
WO2021126827A1 (en) | 2019-12-16 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
US11078246B2 (en) | 2015-08-28 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Peptides binding to Bfl-1 |
WO2021178714A2 (en) | 2020-03-04 | 2021-09-10 | Dana-Farber Cancer Institute, Inc. | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF |
US11142554B2 (en) | 2015-03-18 | 2021-10-12 | Massachusetts Institute Of Technology | Selective Mcl-1 binding peptides |
WO2021216845A1 (en) | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
WO2021222243A2 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
US11298444B2 (en) | 2005-04-01 | 2022-04-12 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
WO2022098848A1 (en) | 2020-11-05 | 2022-05-12 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
WO2023039474A1 (en) | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
WO2023215784A1 (en) | 2022-05-04 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
US11945846B2 (en) | 2016-02-29 | 2024-04-02 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US20020064546A1 (en) * | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
US6258351B1 (en) * | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
CA2316834C (en) * | 1998-01-07 | 2006-01-03 | Shearwater Polymers, Inc. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
US6828412B1 (en) * | 1999-09-03 | 2004-12-07 | School Of Pharmacy, University Of London | Degradable polymers |
US7037992B2 (en) * | 1999-09-29 | 2006-05-02 | Sri International | Olefin copolymers containing hydrolytically cleavable linkages and use thereof in degradable products |
US6288184B1 (en) * | 1999-09-29 | 2001-09-11 | Sri International | Hydrolytically degradable olefin copolymers |
US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
US7265186B2 (en) * | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
JP2005534647A (en) | 2002-06-07 | 2005-11-17 | ダイアックス、コープ | Prevention and reduction of blood loss |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
EP1551876B1 (en) | 2002-10-16 | 2011-03-16 | Purdue Pharma L.P. | Antibodies that bind cell-associated ca 125/0722p and methods of use thereof |
US7311926B2 (en) * | 2002-12-20 | 2007-12-25 | Battelle Memorial Institute | Biocomposite materials and methods for making the same |
CA2536873C (en) * | 2003-08-29 | 2019-09-10 | Dyax Corp. | Poly-pegylated protease inhibitors |
WO2005039641A2 (en) * | 2003-10-15 | 2005-05-06 | The Regents Of The University Of California | Biomacromolecule polymer conjugates |
WO2005115477A2 (en) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
US7282584B2 (en) | 2004-06-16 | 2007-10-16 | Straumann Holding Ag | Methylene blue |
ATE385423T1 (en) | 2004-06-16 | 2008-02-15 | Straumann Holding Ag | COVER MEMBRANE |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US7517914B2 (en) | 2005-04-04 | 2009-04-14 | Boston Scientificscimed, Inc. | Controlled degradation materials for therapeutic agent delivery |
WO2007007392A1 (en) * | 2005-07-11 | 2007-01-18 | Wako Pure Chemical Industries, Ltd. | Novel polymer and method of measuring cholesterol therewith |
EP2412744B1 (en) | 2005-07-18 | 2014-01-22 | Nektar Therapeutics | Method for preparing branched functionalised polymers using branched polyol cores |
GB0515625D0 (en) * | 2005-07-29 | 2005-09-07 | Univ Manchester | Hydrogel particle |
JP2007112924A (en) * | 2005-10-21 | 2007-05-10 | National Institute For Materials Science | Polymer cross-linking agent and liposome or cell cross-linked product using the cross-linking agent |
WO2007149594A2 (en) | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
US8298801B2 (en) * | 2006-07-17 | 2012-10-30 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
EP2044150B1 (en) * | 2006-07-21 | 2014-01-15 | Nektar Therapeutics | Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom |
NZ597098A (en) | 2006-09-28 | 2013-05-31 | Merck Sharp & Dohme | Use of pegylated il-10 to treat cancer |
US8394483B2 (en) | 2007-01-24 | 2013-03-12 | Micron Technology, Inc. | Two-dimensional arrays of holes with sub-lithographic diameters formed by block copolymer self-assembly |
US8083953B2 (en) | 2007-03-06 | 2011-12-27 | Micron Technology, Inc. | Registered structure formation via the application of directed thermal energy to diblock copolymer films |
US8557128B2 (en) | 2007-03-22 | 2013-10-15 | Micron Technology, Inc. | Sub-10 nm line features via rapid graphoepitaxial self-assembly of amphiphilic monolayers |
US8097175B2 (en) | 2008-10-28 | 2012-01-17 | Micron Technology, Inc. | Method for selectively permeating a self-assembled block copolymer, method for forming metal oxide structures, method for forming a metal oxide pattern, and method for patterning a semiconductor structure |
US8294139B2 (en) | 2007-06-21 | 2012-10-23 | Micron Technology, Inc. | Multilayer antireflection coatings, structures and devices including the same and methods of making the same |
US7959975B2 (en) | 2007-04-18 | 2011-06-14 | Micron Technology, Inc. | Methods of patterning a substrate |
US8372295B2 (en) | 2007-04-20 | 2013-02-12 | Micron Technology, Inc. | Extensions of self-assembled structures to increased dimensions via a “bootstrap” self-templating method |
US20080287633A1 (en) * | 2007-05-18 | 2008-11-20 | Drumheller Paul D | Hydrogel Materials |
US8404124B2 (en) | 2007-06-12 | 2013-03-26 | Micron Technology, Inc. | Alternating self-assembling morphologies of diblock copolymers controlled by variations in surfaces |
US8080615B2 (en) | 2007-06-19 | 2011-12-20 | Micron Technology, Inc. | Crosslinkable graft polymer non-preferentially wetted by polystyrene and polyethylene oxide |
US20090075887A1 (en) * | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
EP2205271B1 (en) * | 2007-10-08 | 2014-05-21 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
US8999492B2 (en) | 2008-02-05 | 2015-04-07 | Micron Technology, Inc. | Method to produce nanometer-sized features with directed assembly of block copolymers |
US8101261B2 (en) | 2008-02-13 | 2012-01-24 | Micron Technology, Inc. | One-dimensional arrays of block copolymer cylinders and applications thereof |
CA2711455C (en) * | 2008-02-13 | 2016-06-07 | Hyperbranch Medical Technology, Inc. | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates |
US8426313B2 (en) | 2008-03-21 | 2013-04-23 | Micron Technology, Inc. | Thermal anneal of block copolymer films with top interface constrained to wet both blocks with equal preference |
US8425982B2 (en) | 2008-03-21 | 2013-04-23 | Micron Technology, Inc. | Methods of improving long range order in self-assembly of block copolymer films with ionic liquids |
US8114300B2 (en) | 2008-04-21 | 2012-02-14 | Micron Technology, Inc. | Multi-layer method for formation of registered arrays of cylindrical pores in polymer films |
US8114301B2 (en) | 2008-05-02 | 2012-02-14 | Micron Technology, Inc. | Graphoepitaxial self-assembly of arrays of downward facing half-cylinders |
US8575102B2 (en) * | 2008-08-01 | 2013-11-05 | Nektar Therapeutics | Conjugates having a releasable linkage |
JP5435536B2 (en) * | 2008-09-04 | 2014-03-05 | 学校法人神奈川大学 | Photodegradable block copolymer |
BRPI0920743A2 (en) | 2008-10-01 | 2016-09-20 | Quintessence Biosciences Inc | therapeutic ribonucleases |
WO2010067378A2 (en) | 2008-12-08 | 2010-06-17 | Reliance Life Sciences Pvt. Ltd. | Hydrogel composition |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
JP4704506B2 (en) * | 2009-08-11 | 2011-06-15 | 財団法人川村理化学研究所 | Organic-inorganic composite hydrogel and method for producing the same |
US20110081398A1 (en) * | 2009-10-01 | 2011-04-07 | Tyco Healthcare Group Lp | Multi-mechanism surgical compositions |
US20110081701A1 (en) * | 2009-10-02 | 2011-04-07 | Timothy Sargeant | Surgical compositions |
US8968785B2 (en) * | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
SI2521568T1 (en) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Plasma kallikrein binding proteins |
US8524215B2 (en) * | 2010-08-02 | 2013-09-03 | Janssen Biotech, Inc. | Absorbable PEG-based hydrogels |
US8304493B2 (en) | 2010-08-20 | 2012-11-06 | Micron Technology, Inc. | Methods of forming block copolymers |
CN103635489B (en) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | Blood plasma prekallikrein associated proteins |
US8900963B2 (en) | 2011-11-02 | 2014-12-02 | Micron Technology, Inc. | Methods of forming semiconductor device structures, and related structures |
US9087699B2 (en) | 2012-10-05 | 2015-07-21 | Micron Technology, Inc. | Methods of forming an array of openings in a substrate, and related methods of forming a semiconductor device structure |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | Methods of using interleukin-10 for treating diseases and disorders |
US9229328B2 (en) | 2013-05-02 | 2016-01-05 | Micron Technology, Inc. | Methods of forming semiconductor device structures, and related semiconductor device structures |
CA2914837A1 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US9177795B2 (en) | 2013-09-27 | 2015-11-03 | Micron Technology, Inc. | Methods of forming nanostructures including metal oxides |
JP6660297B2 (en) | 2013-11-11 | 2020-03-11 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Methods of using interleukin-10 to treat diseases and disorders |
CN106459210A (en) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | Compositions and methods for treatment of diabetic macular edema |
JP7059003B2 (en) | 2014-05-14 | 2022-04-25 | トラスティーズ・オブ・ダートマス・カレッジ | Deimmunized lysostaphin and how to use |
WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
JP6675394B2 (en) | 2014-10-22 | 2020-04-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Use of interleukin-10 for the treatment of diseases and disorders |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
AU2016268403A1 (en) | 2015-05-28 | 2017-12-07 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
EP3341012A4 (en) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
EA201891388A1 (en) | 2015-12-11 | 2018-11-30 | Дайэкс Корп. | PLASMA KALLIKREIN INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF THE EXPOSURE OF HEREDITARY ANGIONEUROTIC DOMESTIC |
US11847932B2 (en) | 2017-09-07 | 2023-12-19 | Intuitive Surgical Operations, Inc. | Modified animal organs for use in surgical simulators |
JP6500318B2 (en) * | 2018-04-04 | 2019-04-17 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Heterobifunctional polyethylene glycol derivative and method for preparing the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0658585A2 (en) * | 1993-12-10 | 1995-06-21 | BEHRINGWERKE Aktiengesellschaft | Aminophenylalanine derivatives, process for their production, their use and agents containing them as anti-coagulants |
WO1996020012A2 (en) * | 1994-12-23 | 1996-07-04 | Middlesex Sciences, Inc. | Methods for preparing and purifying macromolecular conjugates |
US5648506A (en) * | 1992-06-04 | 1997-07-15 | Vivorx, Inc. | Water-soluble polymeric carriers for drug delivery |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3419006A (en) | 1966-08-08 | 1968-12-31 | Union Carbide Corp | Novel dressing and use thereof |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3963805A (en) | 1974-10-30 | 1976-06-15 | Union Carbide Corporation | Water swellable poly(alkylene oxide) |
JPH0323530B2 (en) | 1979-03-21 | 1991-03-29 | Nat Res Dev | |
JPS585320A (en) | 1981-07-01 | 1983-01-12 | Toray Ind Inc | Graft copolymer |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5334640A (en) * | 1992-04-08 | 1994-08-02 | Clover Consolidated, Ltd. | Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods |
US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
ATE342295T1 (en) | 1995-07-28 | 2006-11-15 | Genzyme Corp | BIODEGRADABLE MULTIBLOKHYDROGENS AND THEIR USE AS CARRIERS FOR CONTROLLED RELEASE PHARMACOLOGICALLY ACTIVE MATERIALS AND TISSUE CONTACT MATERIALS |
DE69627123T2 (en) * | 1995-08-23 | 2004-02-19 | Mitsui Chemicals, Inc. | NEW ALLYLETHERS, POLYMERS AND SOLID POLYMER ELECTROLYTE |
ZA978537B (en) * | 1996-09-23 | 1998-05-12 | Focal Inc | Polymerizable biodegradable polymers including carbonate or dioxanone linkages. |
US6162241A (en) | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
US6316522B1 (en) * | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
US6448369B1 (en) * | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
CA2316834C (en) * | 1998-01-07 | 2006-01-03 | Shearwater Polymers, Inc. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
US6326276B1 (en) * | 1999-08-10 | 2001-12-04 | United Microelectronics Corp. | Method for forming a capacitor in dram |
-
1999
- 1999-01-06 CA CA002316834A patent/CA2316834C/en not_active Expired - Fee Related
- 1999-01-06 WO PCT/US1999/000594 patent/WO1999034833A1/en active IP Right Grant
- 1999-01-06 DK DK99902172T patent/DK1053019T3/en active
- 1999-01-06 EP EP99902172A patent/EP1053019B1/en not_active Expired - Lifetime
- 1999-01-06 AU AU22214/99A patent/AU755051B2/en not_active Ceased
- 1999-01-06 US US09/226,341 patent/US6362276B1/en not_active Expired - Lifetime
- 1999-01-06 ES ES99902172T patent/ES2211033T3/en not_active Expired - Lifetime
- 1999-01-06 JP JP2000527280A patent/JP3786832B2/en not_active Expired - Fee Related
- 1999-01-06 DE DE1999613316 patent/DE69913316T2/en not_active Expired - Lifetime
- 1999-01-06 AT AT99902172T patent/ATE255422T1/en active
- 1999-01-06 PT PT99902172T patent/PT1053019E/en unknown
-
2001
- 2001-04-02 US US09/824,395 patent/US20010016624A1/en not_active Abandoned
-
2003
- 2003-10-14 US US10/684,946 patent/US7166304B2/en not_active Expired - Fee Related
- 2003-10-14 US US10/684,692 patent/US7214388B2/en not_active Expired - Fee Related
-
2007
- 2007-05-07 US US11/745,235 patent/US20070292931A1/en not_active Abandoned
-
2010
- 2010-08-20 US US12/860,525 patent/US20110009589A1/en not_active Abandoned
-
2012
- 2012-04-13 US US13/446,652 patent/US8497357B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648506A (en) * | 1992-06-04 | 1997-07-15 | Vivorx, Inc. | Water-soluble polymeric carriers for drug delivery |
EP0658585A2 (en) * | 1993-12-10 | 1995-06-21 | BEHRINGWERKE Aktiengesellschaft | Aminophenylalanine derivatives, process for their production, their use and agents containing them as anti-coagulants |
WO1996020012A2 (en) * | 1994-12-23 | 1996-07-04 | Middlesex Sciences, Inc. | Methods for preparing and purifying macromolecular conjugates |
Cited By (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557535B2 (en) | 1996-09-23 | 2013-10-15 | Incept Llc | Methods for preparation of platelet rich plasma |
US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
US7057019B2 (en) | 1996-09-23 | 2006-06-06 | Incept Llc | Crosslinked albumin hydrogels |
US10035880B2 (en) | 1997-11-06 | 2018-07-31 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US8940801B2 (en) | 1997-11-06 | 2015-01-27 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6864327B2 (en) | 1997-11-06 | 2005-03-08 | Nektar Therapeutics Al, Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
WO2000014131A1 (en) * | 1998-09-07 | 2000-03-16 | Polybiomed Limited | Polymerizable material and sheet material derived therefrom |
WO2000015117A1 (en) | 1998-09-17 | 2000-03-23 | Focal, Inc. | Self-cleaning fluid delivery device for medical applications |
US6860870B2 (en) | 1998-09-17 | 2005-03-01 | Focal, Inc. | Self-cleaning fluid delivery device for medical applications |
US7670605B2 (en) | 1999-02-01 | 2010-03-02 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
US7744912B1 (en) | 1999-02-01 | 2010-06-29 | Eidgenossische Technische Hochschule Zurich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
US7413739B2 (en) | 1999-02-01 | 2008-08-19 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
EP2311895A1 (en) | 1999-02-01 | 2011-04-20 | Eidgenössische Technische Hochschule Zürich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
US9951099B2 (en) | 1999-05-18 | 2018-04-24 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US9505801B2 (en) | 1999-05-18 | 2016-11-29 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US10487110B2 (en) | 1999-05-18 | 2019-11-26 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
WO2001026692A1 (en) * | 1999-10-08 | 2001-04-19 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US8183338B2 (en) | 1999-12-22 | 2012-05-22 | Nektar Therapeutics | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
JP4861586B2 (en) * | 1999-12-22 | 2012-01-25 | ネクター セラピューティックス | Sterically hindered derivatives of water-soluble polymers |
JP2003518178A (en) * | 1999-12-22 | 2003-06-03 | シアウォーター・コーポレイション | Sterically hindered derivatives of water-soluble polymers |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
US7132475B2 (en) | 2000-10-19 | 2006-11-07 | Ecole Polytechnique Federale De Lausanne | Block copolymers for multifunctional self-assembled systems |
US8372422B2 (en) | 2000-11-14 | 2013-02-12 | Nektar Therapeutics | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
US8784849B2 (en) | 2000-11-14 | 2014-07-22 | Nektar Therapeutics | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
WO2003005026A2 (en) * | 2001-07-02 | 2003-01-16 | Amersham Biosciences Uk Limited | Chemical capture reagent |
WO2003005026A3 (en) * | 2001-07-02 | 2003-06-26 | Amersham Biosciences Uk Ltd | Chemical capture reagent |
EP2305314A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of antibodies |
EP2279753A2 (en) | 2001-10-10 | 2011-02-02 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
EP2042196A2 (en) | 2001-10-10 | 2009-04-01 | Neose Technologies, Inc. | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
EP2305313A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-alpha (IFNa) |
US8716240B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US8716239B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF |
EP2080525A1 (en) | 2001-10-10 | 2009-07-22 | BioGeneriX AG | Remodeling and Glycoconjugation of Peptides |
EP2305312A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
EP2322229A2 (en) | 2001-10-10 | 2011-05-18 | Novo Nordisk A/S | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
EP2279754A2 (en) | 2001-10-10 | 2011-02-02 | BioGeneriX AG | Remodelling and glycoconjugation of human growth hormone (hGH) |
EP2279755A2 (en) | 2001-10-10 | 2011-02-02 | BioGeneriX AG | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) |
EP2305311A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Glycoconjugation of peptides |
EP2298354A2 (en) | 2001-10-10 | 2011-03-23 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-beta |
US8076292B2 (en) | 2001-10-10 | 2011-12-13 | Novo Nordisk A/S | Factor VIII: remodeling and glycoconjugation of factor VIII |
US7217254B2 (en) | 2002-09-20 | 2007-05-15 | Genzyme Corporation | Multi-pressure biocompatible agent delivery device and method |
WO2004026145A2 (en) | 2002-09-20 | 2004-04-01 | Genzyme Corporation | Multi-pressure biocompatible agent delivery device and method |
US8247381B2 (en) | 2003-03-14 | 2012-08-21 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US8063015B2 (en) | 2003-04-09 | 2011-11-22 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US8853161B2 (en) | 2003-04-09 | 2014-10-07 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP2338333A2 (en) | 2003-04-09 | 2011-06-29 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US9273099B2 (en) | 2003-11-05 | 2016-03-01 | President And Fellows Of Harvard College | Stabilized alpha helical peptides and uses thereof |
US9464115B2 (en) | 2003-11-05 | 2016-10-11 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US8632770B2 (en) | 2003-12-03 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated factor IX |
EP2289567A2 (en) * | 2003-12-22 | 2011-03-02 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring crosslinked protein backbone |
US9700600B2 (en) | 2003-12-22 | 2017-07-11 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
US8858925B2 (en) | 2003-12-22 | 2014-10-14 | Regentis Biomaterials Ltd. | Pegylated fibrinogen precursor molecule |
US9474830B2 (en) | 2003-12-22 | 2016-10-25 | Regentis Biomaterials Ltd. | PEGylated fibrinogen precursor molecule |
WO2005061018A1 (en) * | 2003-12-22 | 2005-07-07 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring protein backbone |
US7842667B2 (en) | 2003-12-22 | 2010-11-30 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
US9120872B2 (en) | 2003-12-22 | 2015-09-01 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
US8007774B2 (en) | 2003-12-22 | 2011-08-30 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
US7338933B2 (en) | 2004-01-08 | 2008-03-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
US9056126B2 (en) | 2004-07-05 | 2015-06-16 | Ascendis Pharma A/S | Hydrogel formulations |
WO2006003014A3 (en) * | 2004-07-05 | 2007-01-11 | Complex Biosystems Gmbh | Hydrogel polymeric conjugates of a prodrug |
US10029015B2 (en) | 2004-07-05 | 2018-07-24 | Ascendis Pharma A/S | Hydrogel formulations |
WO2006003014A2 (en) * | 2004-07-05 | 2006-01-12 | Complex Biosystems Gmbh | Hydrogel polymeric conjugates of a prodrug |
EP2594291A1 (en) * | 2004-07-05 | 2013-05-22 | Ascendis Pharma GmbH | Hydrogel |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
EP2111872A3 (en) * | 2004-07-05 | 2009-12-23 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
EP1625856A1 (en) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
US9200049B2 (en) | 2004-10-29 | 2015-12-01 | Novo Nordisk A/S | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
EP2586456A1 (en) | 2004-10-29 | 2013-05-01 | BioGeneriX AG | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
US10874714B2 (en) | 2004-10-29 | 2020-12-29 | 89Bio Ltd. | Method of treating fibroblast growth factor 21 (FGF-21) deficiency |
US9687216B2 (en) | 2004-11-05 | 2017-06-27 | Incept, Llc | Methods for sealing a vascular puncture |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
EP2514757A2 (en) | 2005-01-10 | 2012-10-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US9707252B2 (en) | 2005-02-09 | 2017-07-18 | Covidien Lp | Synthetic sealants |
US11298444B2 (en) | 2005-04-01 | 2022-04-12 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP2386571A2 (en) | 2005-04-08 | 2011-11-16 | BioGeneriX AG | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
US8404809B2 (en) | 2005-05-25 | 2013-03-26 | Novo Nordisk A/S | Glycopegylated factor IX |
US9505867B2 (en) | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
US9498557B2 (en) | 2006-04-24 | 2016-11-22 | Incept, Llc | Crosslinking methods and applications thereof |
US7597882B2 (en) | 2006-04-24 | 2009-10-06 | Incept Llc | Protein crosslinkers, crosslinking methods and applications thereof |
US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
US8044137B2 (en) | 2006-05-30 | 2011-10-25 | Incept Llc | Materials formable in situ within a medical device |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
WO2008060780A2 (en) | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
EP2952522A1 (en) | 2007-01-31 | 2015-12-09 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
US9527896B2 (en) | 2007-01-31 | 2016-12-27 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
US10301351B2 (en) | 2007-03-28 | 2019-05-28 | President And Fellows Of Harvard College | Stitched polypeptides |
US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
JP2008174755A (en) * | 2008-02-14 | 2008-07-31 | Nektar Therapeutics Al Corp | Hetero-bifunctional polyethylene glycol derivative and method for preparing it |
US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
US9206223B2 (en) | 2008-09-22 | 2015-12-08 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
US9394336B2 (en) | 2008-09-22 | 2016-07-19 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
US10335499B2 (en) | 2008-11-25 | 2019-07-02 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
US9175047B2 (en) | 2009-01-14 | 2015-11-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US10022422B2 (en) | 2009-01-14 | 2018-07-17 | Alleron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US9463004B2 (en) | 2009-05-04 | 2016-10-11 | Incept, Llc. | Biomaterials for track and puncture closure |
EP3266463A1 (en) | 2009-06-09 | 2018-01-10 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
WO2010144629A1 (en) | 2009-06-09 | 2010-12-16 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US9138462B2 (en) | 2009-07-31 | 2015-09-22 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an insulin linker conjugate |
US9457066B2 (en) | 2009-07-31 | 2016-10-04 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an insulin linker conjugate |
US9265723B2 (en) | 2009-07-31 | 2016-02-23 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
US10300109B2 (en) | 2009-09-22 | 2019-05-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8853442B2 (en) | 2009-12-24 | 2014-10-07 | Nisshinbo Holdings, Inc. | Resin crosslinking agent |
EP2518113A4 (en) * | 2009-12-24 | 2013-06-19 | Nisshinbo Holdings Inc | Resin crosslinking agent |
US9957299B2 (en) | 2010-08-13 | 2018-05-01 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US9133276B2 (en) | 2010-09-17 | 2015-09-15 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an exendin linker conjugate |
US10822374B2 (en) | 2010-11-12 | 2020-11-03 | Dana-Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
WO2012065181A2 (en) | 2010-11-12 | 2012-05-18 | Dana Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
US10308699B2 (en) | 2011-10-18 | 2019-06-04 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US9522947B2 (en) | 2011-10-18 | 2016-12-20 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2013102211A2 (en) | 2011-12-29 | 2013-07-04 | Walensky Loren D | Stabilized antiviral fusion helices |
US10077290B2 (en) | 2011-12-29 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized antiviral fusion helices |
US10227380B2 (en) | 2012-02-15 | 2019-03-12 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US10213477B2 (en) | 2012-02-15 | 2019-02-26 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP2012158759A (en) * | 2012-03-27 | 2012-08-23 | Nektar Therapeutics Al Corp | Heterobifunctional polyethylene glycol derivative, and method for preparing the same |
US9617309B2 (en) | 2012-09-26 | 2017-04-11 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
US10669230B2 (en) | 2012-11-01 | 2020-06-02 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
US9845287B2 (en) | 2012-11-01 | 2017-12-19 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
US10081654B2 (en) | 2013-03-13 | 2018-09-25 | President And Fellows Of Harvard College | Stapled and stitched polypeptides and uses thereof |
US11332496B2 (en) | 2013-03-13 | 2022-05-17 | President And Fellows Of Harvard College | Stapled and stitched polypeptides and uses thereof |
US10087215B2 (en) | 2013-03-15 | 2018-10-02 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
EP3572422A1 (en) | 2013-03-15 | 2019-11-27 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
WO2014151369A2 (en) | 2013-03-15 | 2014-09-25 | Dana-Farber Cancer Institute, Inc. | Stabilized ezh2 peptides |
WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
WO2014144148A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
US10227390B2 (en) | 2013-06-14 | 2019-03-12 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
US10533039B2 (en) | 2014-05-21 | 2020-01-14 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
US11377476B2 (en) | 2014-05-21 | 2022-07-05 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
US10471120B2 (en) | 2014-09-24 | 2019-11-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
US11142554B2 (en) | 2015-03-18 | 2021-10-12 | Massachusetts Institute Of Technology | Selective Mcl-1 binding peptides |
US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US10464975B2 (en) | 2015-07-02 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
US11078246B2 (en) | 2015-08-28 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Peptides binding to Bfl-1 |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
JP2016029182A (en) * | 2015-10-28 | 2016-03-03 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Hetero bifunctional polyethylene glycol derivative and preparation method thereof |
US11945846B2 (en) | 2016-02-29 | 2024-04-02 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
WO2018039545A2 (en) | 2016-08-26 | 2018-03-01 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
US11466064B2 (en) | 2016-08-26 | 2022-10-11 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
JP2017197770A (en) * | 2017-06-27 | 2017-11-02 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Heterobifunctional polyethylene glycol derivative, and preparing method thereof |
US11325955B2 (en) | 2017-07-19 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
WO2019018499A2 (en) | 2017-07-19 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
US11834520B2 (en) | 2017-12-15 | 2023-12-05 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides |
WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
WO2019157131A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
US11952432B2 (en) | 2018-02-07 | 2024-04-09 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
WO2019178313A1 (en) | 2018-03-14 | 2019-09-19 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for biomarker detection |
US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
WO2020215005A1 (en) | 2019-04-18 | 2020-10-22 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
CN110759824A (en) * | 2019-09-30 | 2020-02-07 | 兰州交通大学 | Novel method for synthesizing allyl fatty alcohol polyoxyethylene ether carboxylic acid (APEA-3) |
CN110668933A (en) * | 2019-09-30 | 2020-01-10 | 兰州交通大学 | Novel method for synthesizing allyl fatty alcohol polyoxyethylene ether carboxylic acid (APEA-7) |
WO2021126827A1 (en) | 2019-12-16 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
WO2021127493A1 (en) | 2019-12-20 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
WO2021178714A2 (en) | 2020-03-04 | 2021-09-10 | Dana-Farber Cancer Institute, Inc. | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF |
WO2021216845A1 (en) | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
WO2021222243A2 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
WO2022098848A1 (en) | 2020-11-05 | 2022-05-12 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
WO2023039474A1 (en) | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
WO2023215784A1 (en) | 2022-05-04 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU755051B2 (en) | 2002-12-05 |
DE69913316T2 (en) | 2004-11-18 |
DK1053019T3 (en) | 2004-04-13 |
US20010016624A1 (en) | 2001-08-23 |
CA2316834A1 (en) | 1999-07-15 |
WO1999034833A9 (en) | 2005-03-17 |
US20120195846A1 (en) | 2012-08-02 |
US6362276B1 (en) | 2002-03-26 |
US20040086991A1 (en) | 2004-05-06 |
US7214388B2 (en) | 2007-05-08 |
EP1053019B1 (en) | 2003-12-03 |
CA2316834C (en) | 2006-01-03 |
ATE255422T1 (en) | 2003-12-15 |
AU2221499A (en) | 1999-07-26 |
US20110009589A1 (en) | 2011-01-13 |
US7166304B2 (en) | 2007-01-23 |
EP1053019A1 (en) | 2000-11-22 |
US8497357B2 (en) | 2013-07-30 |
JP2003510375A (en) | 2003-03-18 |
US20070292931A1 (en) | 2007-12-20 |
US20040086992A1 (en) | 2004-05-06 |
ES2211033T3 (en) | 2004-07-01 |
PT1053019E (en) | 2004-04-30 |
JP3786832B2 (en) | 2006-06-14 |
DE69913316D1 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1053019B1 (en) | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom | |
US6558658B2 (en) | Delivery of poly (ethylene glycol)-modified molecules from degradable hydrogels | |
EP1019446B1 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor | |
KR20020074461A (en) | Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) | |
AU2002328388B2 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2316834 Country of ref document: CA Ref country code: CA Ref document number: 2316834 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 527280 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 22214/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999902172 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999902172 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 22214/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999902172 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: INTERNATIONAL SEARCH REPORT ADDED (1 PAGE) |